Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NouvNeu001 in Advanced Parkinson's Disease
NCT07102342Phase 2Recruiting
- Sponsor
- iRegene Therapeutics
- Start
- Jan 2026
- Primary completion
- Sep 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NOUVNEU001 in Parkinson's disease (PD), sponsored by iRegene Therapeutics. Primary endpoint: Safety and Tolerability at 48 weeks. Started Jan 2026; status: recruiting.
02
Drugs
NOUVNEU001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07102342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102342.